COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,357 Articles (22,803 medRxiv, 8,554 bioRxiv)

Most recent first Previous |  Page 2003: Articles 20021-20030  | Next

SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray
Pyrc, K., Milewska, A., Duran, E. B., Botwina, P., Lopes, R., Arenas-Pinto, A., Badr, M., Mellor, R., Kalber, T., Fernandez-Reyes, D., Schatzlein, A. G., Uchegbu, I. F.
10.1101/2020.12.10.413609 — Posted: 2020-12-10
Social Media Insights Into US Mental Health Amid the COVID-19 Pandemic. A Longitudinal Twitter Analysis (JANUARY-APRIL 2020)
Valdez, D., ten Thij, M., Bathina, K. C., Rutter, L. A., Bollen, J.
10.1101/2020.12.01.20241943 — Posted: 2020-12-10
The D614G Mutation Enhances the Lysosomal Trafficking of SARS-CoV-2 Spike
Guo, C., Tsai, S. J., Ai, Y., Li, M., Pekosz, A., Cox, A., Atai, N., Gould, S.
10.1101/2020.12.08.417022 — Posted: 2020-12-09
Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies
Armstrong, L., Lange, S. M., de Cesare, V., Matthews, S. P., Nirujogi, R. S., Cole, I., Hope, A., Cunningham, F., Toth, R., Mukherjee, R., Bojkova, D., Gruber, F., Gray, D., Wyatt, P. G., Cinatl, J., Dikic, I., Davies, P., Kulathu, Y.
10.1101/2020.12.09.417741 — Posted: 2020-12-09
Intranasal administration of SARS-CoV-2 neutralizing human antibody prevents infection in mice
Zhang, H., Yang, Z., Xiang, J., Cui, Z., Liu, J., Liu, C.
10.1101/2020.12.08.416677 — Posted: 2020-12-09
Intra-host variability in global SARS-CoV-2 genomes as signatures of RNA editing: implications in viral and host response outcomes
Pathak, A. K., Fatihi, S., Abbas, T., Uppili, B., Mishra, G. P., Ghosh, A., Banu, S., Bhoyar, R. C., Jain, A., Divakar, M. K., Imran, M., Faruq, M., Sowpati, D. T., Raghav, S. K., Thukral, L., Mukerji, M.
10.1101/2020.12.09.417519 — Posted: 2020-12-09
Single dose immunization with a COVID-19 DNA vaccine encoding a chimeric homodimeric protein targeting receptor binding domain (RBD) to antigen-presenting cells induces rapid, strong and long-lasting neutralizing IgG, Th1 dominated CD4+ T cells and strong CD8+ T cell responses in mice
Norheim, G., Stubsrud, E., Skullerud, L. M., Stankovic, B., Chellappa, S., Bjerkan, L., Kuczkowska, K., Muller, E., Sekelja, M., Fredriksen, A. B.
10.1101/2020.12.08.416875 — Posted: 2020-12-09
Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses
Tan, C. C. S., Owen, C. J., Tham, C. Y. L., Bertoletti, A., van Dorp, L., Balloux, F.
10.1101/2020.12.08.415703 — Posted: 2020-12-09
Conformational diversity of CDR region during affinity maturation determines the affinity and stability of Sars-Cov-1 VHH-72 nanobody
George, S.
10.1101/2020.12.08.416164 — Posted: 2020-12-09
Identification of a Novel Susceptibility Marker for SARS-CoV-2 Infection in Human Subjects and Risk Mitigation with a Clinically Approved JAK Inhibitor in Human/Mouse Cells
Spalinger, M. R., Hai, R., Li, J., Santos, A. N., Nordgren, T. M., Tremblay, M. L., Eckmann, L., Hanson, E., Scharl, M., Wu, X., Boland, B. S., McCole, D. F.
10.1101/2020.12.09.416586 — Posted: 2020-12-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).